Ideal Option

Ideal Option specializes in outpatient medication-assisted treatment for addiction, providing essential support to individuals overcoming dependencies on opioids, alcohol, and other substances through accessible care solutions. Founded in 2012 in Kennewick, US, Ideal Option is dedicated to assisting individuals struggling with addiction. The company has focused on outpatient services since its inception without any notable pivots or changes in business strategy. Jeffrey Allgaier is the founder, and Tim Kilgallon currently serves as the CEO.

Ideal Option has successfully completed a funding round in October 2018 with an investment from Varsity Healthcare Partners, although financial terms were not disclosed. Ideal Option is a leading provider of outpatient medication-assisted treatment for individuals struggling with addiction to opioids, alcohol, and other substances. The company offers a range of FDA-approved medications, including Suboxone®, Sublocade®, Brixadi®, and Vivitrol®, designed to alleviate withdrawal symptoms and reduce cravings, thereby facilitating recovery. Their services are structured to provide a primary care-like environment, allowing patients to manage their treatment while maintaining familial and employment ties.

Ideal Option serves a diverse clientele across various geographical markets in the United States, prioritizing accessibility and immediate care by scheduling initial appointments within 24 hours. The company welcomes walk-ins and prioritizes urgent referrals from community partners, such as emergency departments and correctional facilities, ensuring that those in critical need are effectively supported. Ideal Option operates on a revenue model that includes direct patient services funded through various insurance providers, including Medicaid and Medicare, along with options for financial assistance and payment plans. Revenue is generated through patient visits, where services may include consultations, ongoing therapy, and medication prescriptions tailored to individual needs.

The company’s flagship offerings, such as Suboxone® and Vivitrol®, are critical components of their treatment plans, and payments are typically received through insurance reimbursements or out-of-pocket costs at the time of service. Ideal Option’s business structure emphasizes direct-to-consumer interactions, focusing on providing personalized care that adheres to the highest standards of treatment as recognized by The Joint Commission’s Gold Seal of Approval®. While specific details on upcoming products or geographic expansion plans have not been disclosed, the recent investment from Varsity Healthcare Partners in October 2018 positions Ideal Option to potentially enhance its service offerings and reach. The company may utilize this funding to explore new markets or expand existing services to improve accessibility for individuals in need of treatment.